4-PHENYL-2-(1H-1,2,3-TRIAZOL-4-YL)PIPERIDIN-4-OL DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME

4-PHENYL-2-(1H-1,2,3-TRIAZOL-4-YL)PIPERIDIN-4-OL DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME

The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula (I), tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharmaceutically acceptable salts of any of the foregoing, composit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: OLSEN, JESSICA H, GARCIA BARRANTES, PEDRO M, DOLGIKH, ELENA, SENTER, TIMOTHY J, DANIEL, KEVIN B, STONE, STEVEN D, TSAY, CHARLENE, DAKIN, LESLIE A, BRODNEY, MICHAEL A, SHIMIZU, AKIRA J, MEDEK, ALES
Format: Patent
Sprache:eng ; fre
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula (I), tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD). L'invention concerne au moins un composé, un tautomère, un dérivé deutéré ou un sel pharmaceutiquement acceptable choisi parmi les composés de formule I, des tautomères de ceux-ci, des dérivés deutérés de ces composés ou tautomères, et des sels pharmaceutiquement acceptables de l'un quelconque de ceux-ci, des compositions les comprenant, et des procédés d'utilisation associés, comprenant des utilisations dans le traitement de maladies médiées par APOL1, comprenant le cancer du pancréas, la hyalinose segmentaire et focale (HSF) et/ou la néphropathie non diabétique (NND). (Formule I)